



BEST AVAILABLE COPY



PCT/EP200 4 / 0 1 2 4 9 6



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 06 DEC 2004	
WIPO	PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andre Gentry*

Dated 08 AUG 2004

Patents Act 1977
(Rule 16)

The
Patent
Office

THE PATENT OFFICE
M

- 5 NOV 2003

1/177
06NDV03/E849776-3 000245
ED1/7700 0.00-0325828.2

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

- 5 NOV 2003

The Patent Office

Cardiff Road
Newport
South Wales NP10 8QQ

1.	Your reference	IB/G-32713P1/ABR 9929		
2.	Patent application number (The Patent Office will fill in this part)	0325828.2		
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	SANDOZ GMBH BIOCHEMIESTRASSE 10 A-6250 KUNDL, TIROL AUSTRIA Patent ADP number (if you know it) If the applicant is a corporate body, give the country/state of its incorporation AUSTRIA		
4.	Title of invention	Organic Compounds		
5.	Name of your agent (If you have one) "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Craig McLean Novartis Pharmaceuticals UK Limited Patents and Trademarks Wimbleshurst Road Horsham West Sussex RH12 5AB		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. (see note (d))	Yes		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 29

Claim(s) 5

Abstract 1

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date



Craig Mc Lean

4th November 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. Trevor Drew

01403 323069

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*


- 1 -

Organic Compounds


The present invention relates to organic compounds.

We have now surprisingly found organic compounds, e.g. a class of compounds having
 5 pharmacuetical, e.g. antibacterial, activity.

In one aspect the present invention provides a compound of formula



e.g. including a compound of formula



10

wherein

R is hydrogen, CO-R₁ or (C₁₋₈)alkyl, such as methyl, ethyl, n-propyl or n-hexyl, and

R₁ is hydrogen, (C₁₋₈)alkyl, such as ethyl, n-propyl, isopropyl, 2-ethylpropyl, 1,1-dimethylpropyl, n-butyl, isobutyl, t.butyl, n-pentyl, t.butylmethyl, n-hexyl; (C₃₋₈)cycloalkyl, (C₁₋₈)alkoxy-(C₁₋₆)alkyl, (C₁₋₄)alkoxy-(C₁₋₄)alkoxy-(C₁₋₄)alkyl, amino(C₁₋₄)alkyl, halo(C₁₋₆)alkyl, hydroxy(C₁₋₄)alkyl, carboxy(C₁₋₄)alkyl, (C₁₋₄)alkoxycarbonyl-(C₁₋₄)alkyl, (C₆₋₁₈)aryl, heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from S, O or N, or bridged (C₇₋₁₂)cycloalkyl;

15

e.g. wherein

- 2 -

- cycloalkyl is unsubstituted or substituted, such as unsubstituted cycloalkyl or cycloalkyl one or morefold substituted by (C₁₋₄)alkyl or (C₁₋₄)alkoxy, such as 1-methyl-cycloprop-1-yl, 2-methyl-cyclopropyl, 2,2,3,3-tetramethyl-cyclopropyl, 3-methoxy-cyclohexyl, 4-methoxy-cyclohexyl;

5 - amino is unsubstituted or substituted, e.g. unsubstituted or substituted by (C₁₋₄)alkyl, di(C₁₋₄)alkyl, or (C₁₋₄)alkoxycarbonyl; e.g. (C₁₋₄)alkoxycarbonyl, such as methoxycarbonyl,

- aryl is unsubstituted or substituted by amino.


10 **Preferably** in a compound of formula I

-R is hydrogen, (C₁₋₆)alkyl, or CO-R₁,


- R₁ is hydrogen, (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, e.g. unsubstituted (C₃₋₆)cycloalkyl or (C₃₋₆)cycloalkyl substituted by one or more methyl or methoxy; (C₁₋₃)alkoxy-(C₁₋₃)alkyl, methoxy-(C₁₋₂)alkoxy-(C₁₋₂)alkyl, aminomethyl, e.g. including methoxycarbonylamino; halo(C₁₋₄)alkyl comprising one or two halogen atoms; hydroxymethyl, carboxymethyl, methoxycarbonyl-(C₁₋₂)alkyl, phenyl, e.g. phenyl substituted by amino, such as dimethylamino; tetrahydrofuranyl or adamantanyl.

20 In a compound of formula I or I_P, respectively, each single defined substituent may be a preferred substituent, e.g. independently of each other substituent defined.

In another aspect the present invention provides a compound of formula I, wherein R is a group of formula



- 3 -



5

10

If not otherwise defined herein

- alkyl includes (C₁₋₆)alkyl, such as (C₁₋₆)alkyl, e.g. (C₁₋₄)alkyl;
- cycloalkyl includes (C₃₋₆)cycloalkyl, e.g. (C₃₋₆)cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;
- alkoxyalkyl includes (C₁₋₆)alkoxy-(C₁₋₆)alkyl, such as (C₁₋₄)alkoxy-(C₁₋₄)alkyl, e.g. methoxymethyl, ethoxymethyl, 1,1-dimethyl-1-n-propoxymethyl, 1,1-dimethyl-1-isopropoxymethyl, methoxyethyl, 1,1-dimethyl-1-methoxy-methyl;
- alkoxy includes (C₁₋₆)alkoxy, such as (C₁₋₃)alkoxy; e.g. methoxy, ethoxy, propoxy;
- haloalkyl includes halo(C₁₋₆)alkyl, e.g. halo(C₁₋₄)alkyl, comprising one or more halogen atoms, e.g. including (C₁₋₄)alkyl substituted by one or more CF₃, such as -CH(CF₃)₂, 1,1-dimethyl-2-fluoroethyl, or 1,1-dimethyl-2-chloroethyl;
- hydroxyalkyl includes hydroxy(C₁₋₄)alkyl, such as hydroxymethyl;
- carboxyalkyl includes carboxy(C₁₋₄)alkyl, such as carboxymethyl;
- alkoxycarbonylalkyl includes (C₁₋₄)alkoxycarbonyl-(C₁₋₄)alkyl, such as methoxycarbonyl-(C₁₋₄)alkyl, e.g. methoxycarbonylethyl;
- alkoxy-alkoxy-alkyl includes (C₁₋₄)alkoxyl-(C₁₋₄)alkoxy-(C₁₋₄)alkyl, e.g. methoxy-ethoxy-ethyl;
- aminoalkyl includes amino(C₁₋₄)alkyl, such as aminomethyl;
- amino includes unsubstituted amino and amino substituted by (C₁₋₄)alkyl, di(C₁₋₄)alkyl, or (C₁₋₄)alkoxycarbonyl; such as dimethylamino, methoxycarbonylamino;
- heterocyclyl includes heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from S, O and N, e.g. heterocyclyl having 5 ring members, e.g. the heteroatom is selected from O, such as tetrahydrofurane;
- aryl includes (C₆₋₁₈)aryl, such as phenyl;
- bridged cycloalkyl includes cycloalkyl bridged by alkyl, e.g. bridged (C₇₋₁₂)cycloalkyl, such as bridged (C₁₀)cycloalkyl, e.g. adamantanyl;
- halogen includes fluoro, chloro, bromo, iodo, e.g. fluoro, chloro.

Compounds provided by the present invention are hereinafter designated as "compound(s) of (according to) the present invention". A compound of formula I includes a compound of formula I_p. A compound of the present invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a salt and a solvate.

In another aspect the present invention provides a compound of the present invention in the form of a salt.

Such salts include preferably pharmaceutically acceptable salts, although pharmaceutically unacceptable salts are included, e.g. for preparation / isolation / purification purposes.

A salt of a compound of the present invention includes a metal salt or an acid addition salt.

Metal salts include for example alkali or earth alkali salts, e.g. a sodium salt. Acid addition

5 salts include salts of a compound of formula I with an acid, e.g. hydrogen fumaric acid, fumaric acid, naphthalin-1,5-sulphonic acid, hydrochloric acid, deuteriochloric acid.

A compound of the present invention in free form may be converted into a corresponding compound in the form of a salt; and vice versa. A compound of the present invention in free form or in the form of a salt and in the form of a solvate may be converted into a

10 corresponding compound in free form or in the form of a salt in non-solvated form; and vice versa.

A compound of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans conformers. A compound of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form of enantiomers or diastereoisomers and mixtures thereof, e.g. racemates. Substituents at any asymmetric carbon atom may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration. E.g., a compound of formula I has several asymmetric C-atoms and substituents bound to such asymmetric C-atoms may be in the (R)- and in the (S)-


20 configuration, e.g. including mixtures thereof, e.g. as set out in a compound of formula I_P.

Preferably a compound of formula I is a compound of formula I_P. Also a compound of formula I has a double bond and substituents bound to that double bond may be in the form of cis- or trans conformers, or mixtures thereof.

Isomeric mixtures may be separated as appropriate, e.g. according, e.g. analogously, to a method as conventional, to obtain pure isomers. The present invention includes a compound of the present invention in any isomeric form and in any isomeric mixture.


25 The present invention also includes tautomers of a compound of formula I, where tautomers can exist.

30 In the following it is referred to the numbering system of the ring structure and substituents as set out in a compound of formula I below:


I_{NUMBER}

In another aspect the present invention provides a process for the production of a compound of formula I comprising the steps

- a. protecting the carboxy group of position 21 and optionally the hydroxy group attached to the ring structure in position 3 of the ring structure in a compound of formula



II

such as
of formulaII_P

to obtain a compound of formula II, or II_P, respectively, wherein the carboxy group of position 21 is protected and the hydroxy group attached to the ring structure in position 3 is optionally protected,

- b. splitting off the acetyl group from the acetoxy group in position 6 of the ring structure from a compound as obtained in step a., to obtain a compound as obtained in step a, wherein the group attached to position 6 of the ring structure is hydroxy,
 - c1. either hydrogenating the double bond in positions 24 and 25 and, e.g. in the course of double bond hydrogenation, splitting off the protecting group(s) from a compound as obtained in step b., to obtain a compound of formula I, wherein R is H, or
 - c2. reacting a compound as obtained in step b. with a (C₁₋₈)alkylhalogenide, hydrogenating the double bond in positions 24 and 25, and, e.g. in the course of double bond hydrogenation, splitting off the protecting group(s), to obtain a compound of formula I, wherein R is (C₁₋₈)alkyl, or

c3. reacting a compound as obtained in step a. with a compound of formula $R'_1\text{-COOH}$, wherein R'_1 has the meaning of R_1 as defined above, and additionally includes residues as defined in R_1 , wherein functional groups, such as amino, hydroxy, carboxyl, are protected, either in the presence of a condensation agent, or with a compound of formula $R'_1\text{-COOH}$, wherein R'_1 is as defined above, in a reactive form, e.g. in the form of a carboxylic acid halogonide, to obtain a compound as obtained in step b., wherein the group attached to the ring structure in position 6 is a group of formula $\text{CO-R}'_1$, wherein R'_1 is as defined above, hydrogenating the double bond in positions 24 and 25, and, e.g. in the course of double bond hydrogenation, splitting off the protecting group(s), to obtain a compound of formula I, wherein R is a group of formula $\text{CO-R}'_1$, wherein R_1 is as defined above, or wherein R is a group of formula $\text{CO-R}'_1$, wherein R'_1 is as defined above, and optionally splitting of protecting groups in R'_1 , e.g. if (still) present, and

d. isolating a compound of formula I as obtained in step c. from the reaction mixture.

15


The protecting group attached to the carboxy group of position 21 is present, and the protecting group attached at oxygen atom attached to the ring structure in position 3, is optionally present. The reaction works in both cases, but, e.g. to obtain higher purity of the reaction products, both protecting groups are preferably present. Protecting groups include groups as appropriate, e.g. such as conventional, preferably protection groups which may be splitt off by hydrogenation under conditions, under which the double bond in positions 24 and 25 is converted into a single bond. Such groups e.g. include benzyloxymethyl and diphenylmethyl groups, e.g. and benzyl groups. E.g. the protection group attached to the group of position 21 is benzoxyethyl, and the protecting group attached to the oxygen atom which oxygen atom is attached to the ring structure in position 3, is either other than a protecting group, e.g. hydrogen, or benzoxyethyl, or diphenylmethyl.

25


R'_1 has the meaning of R_1 as defined above and additionally includes residues as defined in R_1 , wherein functional groups, such as hydroxy, carboxyl and amino, are protected, e.g. hydroxy or carboxyl are protected by a benzyl group; amino is protected by a benzyloxycarbonyl group; e.g. residues of R_1 having functional groups such as amino, carboxy or hydroxy, are in a protected form, e.g. in the form of benzyloxycarbonylamino, benzyloxy or benzyloxycarbonyl. Such protecting groups may be splitt off in the course of double bond hydrogenation in position 24 and 25, or at an appropriate stage.

30

In another aspect the present invention provides a process for the production of a compound of formula I, wherein R is as defined above, comprising hydrogenating the double bond in positions 24 and 25 and splitting off the protecting group(s), e.g. in the course of double bond hydrogenation, in a compound of formula



such as of formula



wherein

Prot₁ is a protecting group, such as benzyloxymethyl or diphenylmethyl, e.g.

benzyloxymethyl,


Prot₂ is either other than a protecting group, or is a protecting group, e.g. Prot₂ is H, benzyloxymethyl or diphenylmethyl, and R' has the meaning of R as defined above and additionally includes residues as defined in R, wherein functional groups, such as amino, hydroxy, carboxyl groups, are protected.

In a preferred embodiment, a compound of formula I may be produced by a process comprising the steps


a. reacting a compound of formula II, or II_p, respectively,

with benzyloxymethylchloride in the presence of a base, e.g. Hünig's base, in organic solvent, e.g. an halogenated hydrocarbon, such as CH₂Cl₂,


to obtain a compound of formula



such as of formula




- 5 b. reacting a compound of formula IV, or IV_p, respectively, with a base, e.g. an alkali or earth alkali hydroxide, such as NaOH, in organic solvent, e.g. aqueous organic solvent, e.g. in a solvent mixture, such as tetrahydrofuran/MeOH/H₂O, to obtain a compound of formula




- 10 -

such as of formula




- c1. reacting a compound of formula V, or V_p , respectively, with a compound of formula R'_1 -COOH, wherein R'_1 has the meaning of R_1 as defined above and additionally includes residues as defined in R_1 , wherein functional groups, such as amino, hydroxy, carboxyl, groups are protected, in the presence of a condensation agent, such as N'-(3-dimethylamino-propyl)-N-ethylcarbodiimide hydrochloride, and in the presence of a base, e.g. 4-dimethylaminopyridine, in organic solvent, e.g. halogenated hydrocarbon, such as CH_2Cl_2 , or
- 5 c2. reacting a compound of V, or V_p , respectively, with a compound of formula R'_1 -COCl, wherein R'_1 has the meaning of R_1 as defined above, and additionally includes residues as defined in R_1 , wherein functional groups, such as amino, hydroxy, carboxyl groups, are protected, in the presence of a base, such as pyridine and 4-dimethylaminopyridine, to obtain a compound of formula
- 10



15

such as of formula


- 11 -



wherein R'₁ is as defined above,


- d. hydrogenating the double bond in positions 24 and 25 in a compound of formula VI, or VI_P, respectively, e.g. by reaction with H₂, in the presence of a catalyst, such as palladium, e.g. Pd(OH)₂/C, and, e.g. in the course of double bond hydrogenation splitting off protecting group(s), and optionally splitting off protection groups in R'₁, and
- e. isolating a compound of formula I, or I_P, respectively, wherein R is -COR₁, and R₁ is as defined above as obtained in step d. from the reaction mixture.

- 10 In another aspect the present invention provides a compound of formula



such as of formula

- 12 -




wherein

- Prot₁ is a protecting group, such as benzyloxymethyl or diphenylmethyl, e.g. benzyloxymethyl, and
- 5 Prot₂ is either other than a protecting group, or is a protecting group, e.g. Prot₂ is H, benzyloxymethyl or diphenylmethyl, and R'₁ is as defined above, e.g. which compounds of formula VII, or VII_p, respectively, are useful as intermediates in the production of a compound of formula I, or I_p, respectively.
- 10 A compound of formula VII, or VII_p, respectively, includes compounds of formulae VI, or VI_p, respectively.

- In another aspect the present invention provides a compound of formula IV, or IV_p, respectively, and of formula V, or V_p, respectively and of formula VI, or VI_p, respectively,
- 15 wherein R'₁ is as defined above, which compounds are useful as intermediates in the production of a compound of formula I, or I_p, respectively, wherein R is a group -CO-R₁.

In another aspect the present invention provides a compound of formula



1000

1000



1000

1000

1000

1000

- 1000

1000

1000

1000

An intermediate of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans conformers, similarly as described above for a compound of the present invention. Isomeric mixtures may be separated as appropriate, e.g. according, e.g. analogously, to a method as conventional, to obtain pure isomers. The present invention includes an intermediate of the present invention in any isomeric form and in any isomeric mixture.

The present invention also includes tautomers of an intermediate of the present invention, where tautomers can exist.

10 In an intermediate of the present invention beside the (Prot-) protected groups, further functional groups, where present, optionally may be in protected form, e.g. amino, hydroxy or carboxyl groups, as indicated above; or may be in the form of a salt, where a salt-forming group is present. Protecting groups, optionally present beside Prot₁ and Prot₂, may be removed at an appropriate stage, e.g. according, e.g. analogously, to a method as
15 conventional.

A compound of formula I, or I_P, respectively, obtained by a process provided by the present invention may be converted into another compound of formula I, or I_P, respectively, e.g. or a compound of formula I, or I_P, respectively, obtained in free form may be converted into a salt
20 of a compound of formula I, or I_P, respectively, and vice versa.

Any compound described herein, e.g. a compound of the present invention and intermediates of formula II, II_P, III, III_P, IV, IV_P, V, V_P, VI, VI_P, VII, VII_P, VIII and VIII_P may be prepared as appropriate, e.g. according, e.g. analogously, to a method as conventional, e.g.
25 or as specified herein.

The compounds of the present invention, e.g. including a compound of formula I and of formula I_P, exhibit pharmacological activity and are therefore useful as pharmaceuticals. The compounds of the present invention, e.g. including a compound of formula I and of
30 formula I_P, exhibit pharmacological activity and are therefore useful as pharmaceuticals. E.g., the compounds of the present invention show antimicrobial, e.g. antibacterial activity against gram positive bacteria and gram negative, such as Staphylococcus, e.g. S. aureus, MRSA (Methicillin Resistant S. aureus), MSSA (Methicillin Sensitive S. aureus), Enterococcus, e.g. E. faecalis, E. faecium, Moraxella, e.g. M. catarrhalis,

in vitro in the Agar Dilution Test and/or Micro Dilution Test for bacteria according to National Committee for Clinical Laboratory Standards (NCCLS) 1993,

- Document M7-A4, Vol. 20, No.2, 2000: "Methods for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically" - Third Edition, Approved Standard"; and

5 - Document M26-A, Vo. 19, No. 18, 1999: Methods for determining antibactericidal activity of antimicrobial agents,

- Document M11-A3 for anaerobic bacteria,

in a concentration from about 0.1 to ca. 25.6 µg/ml, e.g. using strains including

Staphylococcus aureus (ATCC 29213 and ATCC 29506); Enterococcus faecalis ATCC

10 29212;

and in vivo in the septicaemia mouse model, in accordance to the method description Nr.

159 A-5, approved by Austrian Health Authorities (MA 58, no. 2968/95 of 12-Oct-1995), e.g. when administered at dosages from 0.05 to 50 mg/kg body weight.

E.g., mice infected with Staphylococcus aureus (ATCC 49951, MSSA), and treated orally 1

15 and 4 hours after infection with a compound of example 1, e.g. in the form of its sodium salt,

show an ED₅₀ value of ca. 8.52 mg/kg body weight (ranging from 3.92 to 12.72). Mice

infected with S. aureus B29 (clinical isolate, MRSA) and treated orally 1 and 4 hours after

infection with a compound of example 1, e.g. in the form of its sodium salt, show an ED₅₀

value of ca. 4.66 mg/kg body weight, (ranging from 1.58 to 7.80). The ED₅₀ values are

20 calculated by Probit analysis of the administered dosages of compounds. Activity is

determined by numbers of surviving animals per group of 8 or 6 mice, respectively, per

dosage unit on day 5 after infection.

The compounds of the invention show a surprising overall activity spectrum.

It has, for example, been determined that the MIC (µg/ml) of the compound of Example 1,

25 e.g. in the form of its sodium salt, against, for example Moraxella catarrhalis is of ca. 0.1 to

0.5; against Staphylococcus aureus is of ca. 0.2 to 12.5, and of Enterococcus faecalis is of

ca. 6.4.

The compounds of the present invention are therefore useful for the treatment of microbial,

30 e.g. bacterial diseases, e.g. the treatment of diseases associated with bacterial infections.

Treatment includes treatment and prevention (prophylaxis).

In another aspect the present invention provides a compound of the present invention for use

as a pharmaceutical, e.g. in the treatment of diseases associated with microbial, such as

bacterial infections.

In another aspect the present invention provides the use of a compound of the present invention for the manufacture of a medicament, e.g. in the form of a pharmaceutical composition, for the treatment of a microbial disease, such as bacterial diseases, for example of diseases associated with bacterias such as *Staphylococcus* spp. and *Moraxella catarrhalis*.

The compound of example 1 is a preferred compound of the present invention. It has, for example been determined that the minimum inhibitory concentration, e.g. MIC₉₀ ($\mu\text{g/ml}$), of the compound of Example 1, e.g. in the form of its sodium salt, against, for example *S. aureus* (MRSA) is of about 0.4. It is therefore, indicated that for the treatment of bacterial diseases, the compounds of the present invention may be administered to larger mammals, for example humans, by similar modes of administration at similar dosages than conventionally used with Linezolid.

In a further aspect the present invention provides a method of treatment of microbial, e.g. bacterial, diseases, e.g. diseases mediated by bacterias such as *Staphylococcus* spp. and *Moraxella*, which treatment comprises administering to a subject in need of such treatment an effective amount of a compound of the present invention; e.g. in the form of a pharmaceutical composition, e.g. in combination with another pharmaceutically active agent.

For pharmaceutical use a compound of the present invention includes one or more, preferably one, compounds of the present invention, e.g. a combination of two or more compounds of the present invention.

For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the chemical nature and the pharmacokinetic data of a compound of the present invention employed, the individual host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.01g to about 1.0 g of a compound of the present invention; conveniently administered, for example, in divided doses up to four times a day.

A compound of the present invention may be administered by any conventional route, for

example enterally, e.g. including nasal, buccal, rectal, oral, administration; parenterally, e.g. including intravenous, intramuscular, subcutaneous administration; or topically; e.g. including epicutaneous, intranasal, intratracheal administration;

5 e.g. in form of coated or uncoated tablets, capsules, (injectable) solutions, solid solutions, suspensions, dispersions, solid dispersions; e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, or in the form of suppositories.

The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt, e.g. an acid addition salt or metal salt; or in free form; 10 optionally in the form of a solvate. The compounds of the present invention in the form of a salt exhibit the same order of activity as the compounds of the present invention in free form; optionally in the form of a solvate.

A compound of the present invention may be used for pharmaceutical treatment according to 15 the present invention alone, or in combination with one or more other pharmaceutically active agents. Such other pharmaceutically active agents include other antibacterials, e.g. penicillins, cephalosporins, macrolides. Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. 20 with instruction for co-administration; and free combinations in which the pharmaceutically active agents are packaged separately, but instruction for simultaneous or sequential administration are given.

In another aspect the present invention provides a pharmaceutical composition comprising a 25 compound of the present invention in association with at least one pharmaceutical excipient, e.g. appropriate carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers,

30 e.g. and further comprising another pharmaceutically active agent.

Such compositions may be manufactured according, e.g. analogously, to a method as conventional, e.g. by mixing, granulating, coating, dissolving or lyophilizing processes. Unit


dosage forms may contain, for example, from about 0.5 mg to about 1000 mg, such as 1 mg to about 500 mg.

In the following Examples all temperatures are in degrees Celsius (°C) and are uncorrected.

5 The following abbreviations are used:

Bn	benzyl	BOM	benzyloxymethyl
Cbz	benzyloxycarbonyl	DMAA	N,N-dimethylacetamide
DMAP	4-dimethylaminopyridine	LiHMDS	Lithium bis(trimethylsilyl)amide
EDCI	N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide in the form of a hydrochloride		
10 EtOAc	ethyl acetate	EX	Example
PE	petrolether	PPTS	pyridinium p-toluenesulfonat
rt	room temperature	THF	tetrahydrofurane
DPM	Diphenylmethyl		

Cephalosporin P1 is a compound of formula II_P.



EXAMPLE 1

6-O-isobutyryl-24, 25-dihydro-Cephalosporin P1 (compound of formula I, wherein R is -COR₁, wherein R₁ is isopropyl):

A. 3-O-Benzylloxymethyl-cephalosporin P1-benzylloxymethylester (compound of formula IV_P)

- 5 9.68 ml of BOM-Cl are added to a solution of 10 g of Cephalosporin P1 and 12.2 ml of Hünig's base in 40 ml of anhydrous CH₂Cl₂ at -10 °C. The reaction mixture obtained is stirred for 15 minutes and allowed to warm up to rt, and stirring is continued under argon for 24 hours. H₂O is added to the mixture obtained, two phases are obtained and are separated. The organic layer obtained is washed with H₂O, brine and saturated aqueous Na₂CO₃-
- 10 solution, dried and solvent is evaporated. 3-O-Benzylloxymethyl-Cephalosporin P1 benzylloxymethylester is obtained.

¹H-NMR (200MHz, DMSO+D₂O): δ (ppm) = 7.32-7.37 (m, 10H, arom.-H), 5.66 (d, J=8.5Hz, H-16), 5.32 (dd, J=6.2Hz, J=16.3Hz, 2H, BOM-CH₂), 5.08 (t, J=6.4Hz, 1H, 24-H), 4.57-4.83 (m, 7H, 6-H, 3x BOM-CH₂), 3.54 (s, 1H, 3-H), 3.34 (s, 1H, 7-H), 2.00/1.84 (2s, 2 x 3H, H-34, H-36).

- 15 B. 3-O-Benzylloxymethyl-6-deacetyl-Cephalosporin P1 benzylloxymethylester (compound of formula V_P)

- 6.97 ml of 2N NaOH are added at 0°C to a solution of 11.38 g of 3-O-benzylloxymethyl-Cephalosporin P1 benzylloxymethylester in 75 ml of a mixture of THF/MeOH/H₂O = 5/4/1. To the reaction mixture obtained 20 ml of THF are added, in order to obtain a clear solution
- 20 which is stirred at rt for 16 hours. 1.4 ml of 2N NaOH are added to the mixture obtained, solvent from the mixture obtained is evaporated, the residue obtained is distributed between H₂O and Et₂O, the mixture obtained is extracted, the organic layer obtained is washed with H₂O and brine, dried and solvent is evaporated. 3-O-Benzylloxymethyl-6-deacetyl-Cephalosporin P1 benzylloxymethylester is obtained.

- 25 ¹H-NMR (200MHz, DMSO): δ (ppm) = 7.26-7.32 (m, 10H, arom.-H), 5.68 (d, J=8.2Hz, H-16), 5.32 (dd, J=6.2Hz, J=18.8Hz, 2H, BOM-CH₂), 5.08 (t, 1H, 24-H), 4.47-4.81 (m, 6H, 3x BOM-CH₂), 3.51 (s, 1H, 3-H), 3.49/3.34 (2s, 1H, 6-H, 7-H), 1.85 (1s, 3H, H-34).

- ¹³C-NMR (50MHz, DMSO): δ (ppm) = 169.56, 168.57, 149.13, 138.18, 137.10, 131.67, 129.09, 128.21, 128.15, 127.66, 127.50, 127.35, 127.27, 123.0, 92.97, 88.18, 82.84, 78.32, 75.84, 73.75, 71.12, 68.62, 49.05, 47.88, 43.55, 42.48, 36.23, 35.66, 30.02, 28.13, 27.89, 25.96, 25.59, 25.38, 22.86, 22.37, 20.75, 20.37, 18.71, 18.32, 17.43.
- 30

C. 3-O-Benzylloxymethyl-6-O-ⁱbutyryl-Cephalosporin P1 benzylloxymethylester (compound of formula VI_P, wherein R₁ is isopropyl)

1.4 ml of isobutyric acid are added to a solution of 8.68 g 3-O-benzyloxymethyl-6-deacetyl-Cephalosporin P1 benzyloxymethylester and 1.1 g of DMAP in anhydrous CH_2Cl_2 under argon at 0 °C. 2.80 g of EDCI are added to the mixture obtained and the mixture obtained is stirred at rt overnight. The mixture obtained is concentrated and the concentration residue obtained is distributed between EtOAc and H_2O and extracted. The organic layer obtained is washed with H_2O , brine and saturated, aqueous Na_2CO_3 -solution, dried and solvent is evaporated. 3-O-Benzyloxymethyl-6-O-isobutyryl-Cephalosporin P1 benzyloxymethylester is obtained. $^1\text{H-NMR}$ (200MHz, DMSO): δ (ppm) = 7.26-7.32 (m, 10H, arom.-H), 5.67 (d, $J=8.3\text{Hz}$, H-16), 5.32 (dd, $J=6.2\text{Hz}$, $J=16.7\text{Hz}$, 2H, BOM- CH_2), 5.04-5.10 (m, 2H, OH, 24-H), 4.49-4.82 (m, 8H, OH, 6-H, 3x BOM- CH_2), 3.53 (s, 1H, 3-H), 3.27 (d, 1H, 7-H), 1.84 (1s, 3H, H-34), 1.05 (m, cont. 2 x 3'- CH_3).

$^{13}\text{C-NMR}$ (50MHz, DMSO): δ (ppm) = 175.27, 169.61, 168.48, 149.14, 138.10, 137.0, 131.86, 129.25, 128.22, 128.17, 127.67, 127.50, 127.35, 122.97, 92.97, 88.22, 79.90, 77.79, 77.54, 73.71, 71.14, 68.69, 54.76, 47.92, 42.89, 35.83, 35.19, 33.56, 30.93, 28.15, 27.88, 25.82, 25.62, 25.39, 23.21, 22.89, 21.00, 20.32, 18.75, 18.25, 17.43, 17.13, 16.94, 16.57.

D. 6-O-isobutyryl-24, 25-dihydro-Cephalosporin P1 (compound of formula I, wherein R is -
COR₁, wherein R₁ is isopropyl)

4.10 g of 3-O-benzyloxymethyl-6-O-isobutyryl-Cephalosporin P1 benzyloxymethylester are hydrogenated at 1 atm in the presence of $\text{Pd}(\text{OH})_2/\text{C}$ in 20ml of a mixture of EtOAc /MeOH = 10 /1 overnight, the mixture obtained is filtered and solvent is evaporated. 6-O-isobutyryl-24, 25-dihydro-Cephalosporin P1 is obtained.

Example 2

3-O-Benzyloxymethyl-6-O-pivaloyl-Cephalosporin P1 benzyloxymethylester
(compound of formula VI_P, wherein R₁ is t.butyl)









1.31 ml of pivaloyl chloride are added at rt to a solution of 5.504 g of 3-O-benzyloxymethyl-6-deacetyl-Cephalosporin P1 benzyloxymethylester and 1.13 g of DMAP in anhydrous pyridine under argon. The mixture obtained is stirred under argon at 50°C for 20 hours. The mixture obtained is poured over ice and the mixture obtained is extracted with EtOAc. The organic layer obtained is washed with H_2O and brine, dried, and solvent is evaporated. 3-O-Benzyloxymethyl-6-O-pivaloyl-Cephalosporin P1 benzyloxymethylester is obtained. Splitting off the benzyloxymethyl protecting group and hydrogenation of the double bond is carried out analogously to Example 1, step D..











Analogously to the methods as described in examples 1 and 2, but using appropriate starting materials, compounds of formula I, wherein R is as defined in TABLE 1 below, are obtained.










¹H-NMR data (in DMSO, if not otherwise indicated) of the compounds are also set out in









TABLE 1.

TABLE 1

EX	R	¹ H-NMR
1		5.82 (d, J=8.7 Hz, 1H, 16-H), 4.53 (d, J=10.6 Hz, 1H, 6-H), 3.71 (d, J=2.1Hz, 1H, 3-H), 3.40 (s, 1H, 7-H), 2.49-2.56 (m, 3H, 13-H, 2'-H, 22a-H), 2.09-2.35 (m, 5H, 22b-H, 5-H, 8-H, 12a-H, 15a-H), 1.94 (s, 3H, 34-CH ₃), 1.82-1.89 (m, 3H, 4-H, 2a-H, 11a-H), 1.67-1.72 (m, 3H, 1a-H, 12b-H, 2b-H), 1.35-1.53 (m, 6H, 25-H, 11b-H, 23-CH ₂ , 15b-H, 1b-H), 1.14-1.19 (m, 14H, 19-CH ₃ , 2 x 3'-CH ₃ , 30-CH ₃ , 24-CH ₂), 1.03 (s, 3H, 18-CH ₃), 0.89 (d, J=6.9Hz, 3H, 28-CH ₃), 8.86 (d, J=6.9Hz, 6H, 26-CH ₃ , 27-CH ₃)
2		5.61 (d, J=8.1Hz, 1H, 16-H), 4.60 (d, J=9.7Hz, 1H, 6-H), 3.47 (s, 1H, 3-H), 3.19 (s, 1H, 7-H), 1.88 (s, 3H, 34-CH ₃), 1.13 (s, 9H, 3 x 3'-CH ₃)
3		5.62 (d, J=8.2Hz, 1H, 16-H), 4.63 (dd, J=9.7Hz, J=2.0Hz, 1H, 6-H), 3.47 (s, 1H, 3-H), 3.19 (d, J=2.0Hz, 1H, 7-H), 1.89 (s, 3H, 34-CH ₃), 1.21-2.44 (m, 2'-H, 3'-CH ₂ , 4'-CH ₂)
4		5.64 (d, J=7.9Hz, 1H, 16-H), 4.65 (d, J=10.2Hz, 1H, 6-H), 3.48 (s, 1H, 3-H), 3.10 (s, 1H, 7-H), 1.92-2.56 (m, 9H, cont. 2'-CH ₂), 1.89 (s, 3H, 34-CH ₃), 1.03 (d, J=7.0Hz, 3 H, 3'-CH ₃)
5		5.59 (d, J=8.3 Hz, 1H, 16-H), 4.60 (d, J=9.9Hz, 1H, 6-H), 3.47 (s, 1H, 3-H), 3.30 (s, 1H, 7-H), 1.92-2.56 (m, 9H, cont. 2'-CH ₂), 1.89 (s, 3H, 34-CH ₃), 0.77-1.80 (m, cont. 3'-CH ₂ , 4'-CH ₃)
6		5.57 (d, J=8.3Hz, 1H, 16-H), 4.65 (dd, J=7.9Hz, J=2.5Hz, 1H, 6-H), 3.93 (dd, J=17.1, J=28.5, 2H, 2'-CH ₂), 3.45 (s, 1H, 3-H), 3.32 (d, J=2.5Hz, 1H, 7-H)
7		5.60 (d, J=8.2 Hz, 1H, 16-H), 4.60 (d, J=10.0Hz, 1H, 6-H), 3.48 (s, 1H, 3-H), 3.31 (s, 1H, 7-H), 1.92-2.56 (m, 9H, cont. 2'-CH ₂), 1.89 (s, 3H, 34-CH ₃), 0.76-1.80 (m, cont. 3'-CH ₂ , 4'-CH ₂ , 5'-CH ₂ , 6'-CH ₂ , 7'-CH ₃)
8		5.62 (d, J=6.8Hz, 1H, 16-H), 4.70 (d, J=9.9Hz, 1H, 6-H), 3.84-4.20 (m, 2H, 2'-CH ₂), 3.32-3.44 (m, 5H, 3-H, 7-H, -OCH ₃)

EX	R	¹ H-NMR
9		5.62 (d, 1H, 16-H), 4.62 (d, 1H, 6-H), 3.45 (s, 1H, 3-H), 3.33 (s, 1H, 7-H), 1.92-2.56 (m, 9H, cont. 2'-CH ₂), 1.88 (s, 3H, 34-CH ₃), 0.76-1.80 (m, cont. 3'-CH ₂ , 4'-CH ₂ , 5'-CH ₃)
10		5.61 (d, 1H, J=8.2Hz, 16-H), 4.61 (d, J=9.3Hz, 1H, 6-H), 3.48 (s, 1H, 3-H), 3.31 (s, 1H, 7-H), 1.92-2.56 (m, 9H, cont. 2'-CH ₂), 1.87 (s, 3H, 34-CH ₃), 0.76-1.80 (m, cont. 3'-CH ₂ , 4'-CH ₂ , 5'-CH ₂ , 6'-CH ₃)
11		5.61 (d, J=8.3Hz, 1H, 16-H), 4.63 (d, J=10.1Hz, 1H, 6-H), 3.53-3.59 (m, 2H, 2'-CH ₂), 3.47 (s, 1H, 3-H), 3.32 (s, 1H, 7-H), 3.22 (s, 3H, -OCH ₃)
12		8.21 (s, 1H, 1'-H), 5.62 (d, J=7.9Hz, 1H, 16-H), 4.66 (dd, 1H, 6-H), 3.48 (s, 1H, 3-H), 3.38 (d, J=2.8Hz, 1H, 7-H), 1.89 (s, 3H, 34-CH ₃)
13		8.28 (dd, J=5.8Hz, 1H, NH), 5.60 (d, J=8.1Hz, 1H, 16-H), 4.64 (dd, J=8.3Hz, J=2.4Hz, 1H, 6-H), 3.60 (dd, J=5.8Hz, 2'-CH ₂), 3.47 (s, 1H, 3-H), 3.34 (d, J=2.4Hz, 1H, 7-H), 1.85/1.87 (2s, 2x3H, 34-CH ₃ , 4'-CH ₃)
14		5.61 (d, J=7.7Hz, 1H, 16-H), 4.60 (d, J=9.8Hz, 1H, 6-H), 3.47 (s, 1H, 3-H), 3.25 (s, 1H, 7-H), 2.48-2.84 (m, 2'-H), 1.88 (s, 3H, 34-CH ₃), 1.00-2.45 (m, 3'-CH ₂ , 4'-CH ₂ , 5'-CH ₂ , 6'-CH ₂)
15		5.61 (d, J=8.3Hz, 1H, 16-H), 4.61 (d, J=10.0Hz, 1H, 6-H), 3.46 (s, 1H, 3-H), 3.27 (s, 1H, 7-H), 3.09 (quin, J=8.3Hz, 2'-H)
16		5.64 (d, J=8.33Hz, 1H, 16-H), 4.63 (d, J=10.0Hz, 1H, 6-H), 3.48 (s, 1H, 3-H), 3.35 (s, 1H, 7-H), 1.95-2.50 (m, cont. 2'-CH ₂ , 3'-H), 1.90 (s, 3H, 34-CH ₃), 0.96/0.95/0.93/0.92 (4s, 4x4'-CH ₃)
17		5.61 (d, J=8.3Hz, 1H, 16-H), 4.67 (d, 1H, 6-H), 3.47 (s, 1H, 3-H), 3.09-3.40 (m, 5H, 7-H, 2'-CH ₂ , NH ₂)
18		5.60 (d, J=8.5Hz, 1H, 16-H), 4.60 (d, J=10.0Hz, 1H, 6-H), 3.49 (s, 1H, 3-H), 3.32 (s, 1H, 7-H), 1.87 (s, 3H, 34-CH ₃), 1.12/1.00 (2s, 2x3H, 4'-CH ₃)

EX	R	¹ H-NMR
19		5.61 (d, J=7.9Hz, 1H, 16-H), 4.60 (d, J=10.3Hz, 1H, 6-H), 3.49 (s, 1H, 3-H), 3.35 (s, 1H, 7-H), 1.89 (s, 3H, 34-CH ₃), 1.00 (s, 9H, 4'-CH ₃)
20		5.63 (d, J=8.3Hz, 1H, 16-H), 4.59 (d, J=9.9Hz, 1H, 6-H), 3.47 (s, 1H, 3-H), 3.24 (s, 1H, 7-H), 0.99-2.35 (m, cont. 2'-H, 3'-CH ₂ , 4'-CH ₂ , 5'-CH ₂ , 6'-CH ₂ , 7'-CH ₂)
21		5.64 (d, J=8.3Hz, 1H, 16-H), 4.72 (d, J=8.8Hz, 1H, 6-H), 3.90-4.18 (m, 2H, 2'-CH ₂), 3.36-3.57 (m, 4H, 3-H, 7-H, 4'-CH ₂)
22		5.61 (m, 1H, 16-H), 4.6-4.7 (m, 1H, 6-H), 4.19-4.35 (m, 1H, H-2'), 3.80 (m, 2H, 4'-CH ₂), 3.34-3.45 (m, 2H, 3-H, 7-H)
23		5.62 (d, J=7.5Hz, 1H, 16-H), 4.65 (d, J=9.5Hz, 6-H), 3.03-3.93 (m, 3'-CH ₂ , 5'-CH ₂ , 3-H, 7-H)
24		5.61 (d, J=8.3Hz, 1H, 16-H), 4.60 (d, J=11.2Hz, 6-H), 3.47 (s, 1H, 3-H), 3.28 (s, 1H, 7-H), 1.04 (s, 3H, -CH ₃ (3'-C))
25		5.64 (d, J=8.3Hz, 1H, 16-H), 4.72 (d, J=8.9Hz, 1H, 6-H), 4.09 (dd, 2H, 2'-CH ₂), 3.60-3.64/3.46-3.50 (2m, 5H, 4'-CH ₂ , 5'-CH ₂ , 3-H), 3.37 (s, 1H, 7-H), 3.27 (s, 3H, -OCH ₃)
26		5.84 (d, J=8.7Hz, 1H, 16-H), 4.77 (d, J=10.5Hz, 6-H), 4.10 (sept., 1H, 2'-H), 3.74 (s, 1H, 3-H), 3.50 (s, 1H, 7-H)
27		5.58 (d, J=8.3Hz, 1H, 16-H), 4.57 (d, J=10.1Hz, 6-H), 3.57 (s, 3H, -OCH ₃), 3.45 (s, 1H, 3-H), 3.29 (s, 1H, 7-H).

EX	R	¹ H-NMR
28		5.61 (d, J=8.1Hz, 1H, 16-H), 4.60 (d, J=9.8Hz, 1H, 6-H), 3.10-3.48 (m, 6H, 5'-H, OCH ₃ , 3-H, 7-H)
29		5.61 (d, J=8.0Hz, 1H, 16-H), 4.61 (d, J=10.0Hz, 1H, 6-H), 3.49 (s, 1H, 3-H), 3.05-3.30 (m, 5H, 4'-H, OCH ₃ , 7-H)
30		5.62 (d, J=8.2Hz, 1H, 16-H), 4.59 (d, J=9.7Hz, 1H, 6-H), 3.45 (s, 1H, 3-H), 3.17 (d, 1H, 7-H), 1.40-2.45 (m, cont. adamantyl - CH and CH ₂)
31		5.63 (d, 1H, 16-H), 4.60 (d, J=10.1Hz, 1H, 6-H), 3.46 (s, 1H, 3-H), 3.26 (s, 1H, 7-H), 1.87 (s, 3H, 34-CH ₃), 1.00-1.24 (m, cont. 12H, 2 x CH ₃ (C-2'), 4'-CH ₃)
32		5.63 (d, J=8.2Hz, 1H, 16-H), 4.56 (d, J=10.2Hz, 6-H), 3.45 (s, 1H, 3-H), 3.29 (s, 1H, 7-H), 1.15 (s, 12H, 4 x -CH ₃ (3'-C))
33		5.63 (d, J=8.2Hz, 1H, 16-H), 4.60 (d, J=10.0Hz, 6-H), 3.45 (s, 1H, 3-H), 3.24 (s, 1H, 7-H), 0.70-1.80 (m, 39H, cont. -CH ₃ (2'-C), 3'-CH ₂ , 4'-CH ₂)
34		5.62 (d, J=8.2Hz, 1H, 16-H), 4.63 (d, J=9.8Hz, 1H, 6-H), 3.73 (dd, J=10.7Hz, J=15.9Hz, 2H, -CH ₂ Cl), 3.47 (s, 1H, 3-H), 3.35 (d, 1H, 7-H), 1.87 (s, 3H, 34-CH ₃), 1.20 (s, 6H, 2 x CH ₃ (C-2'))
35		5.63 (d, J=8.4Hz, 1H, 16-H), 4.66 (d, J=10.0Hz, 1H, 6-H), 3.46 (s, 1H, 3-H), 3.26 (d, 1H, 7-H), 3.16 (s, 3H, OCH ₃), 1.87 (s, 3H, 34-CH ₃), 1.31 (s, 6H, 2 x CH ₃ (C-2'))

EX	R	¹ H-NMR
36		5.62 (d, J=8.1Hz, 1H, 16-H), 4.65 (d, J=9.9Hz, 1H, 6-H), 3.17-3.55 (m, 4H, 3-H, 7-H, -OCH ₂), 1.87 (s, 3H, 34-CH ₃), 1.32 (s, 6H, 2 x CH ₃ (C-2'))
37		7.28-7.38 (m, 3H, arom.H), 6.93 (d, 1H, arom.H), 5.76 (d, J=8.6Hz, 1H, 16-H), 4.79 (d, J=11.2Hz, 1H, 6-H), 3.70 (s, 1H, 3-H), 3.61 (d, 1H, 7-H), 2.98 (s, 6H, -N(CH ₃) ₂)
38		5.77 (d, J=8.4Hz, 1H, 16-H), 4.51 (d, J=10.5Hz, 1H, 6-H), 3.60-3.74 (m, 2H, 3-H, -OCH(CH ₃) ₂), 3.34 (s, 1H, 7-H), 1.88 (s, 3H, 34-CH ₃), 1.00-1.50 (m, cont., 2 x CH ₃ (C-2')), -OCH(CH ₃) ₂)
39		7.82 (d, J=8.9Hz, 2H, arom.H), 6.57 (d, J=8.9Hz, 2H, arom.H), 5.71 (d, J=8.4Hz, 1H, 16-H), 4.67 (d, J=10.5Hz, 1H, 6-H), 3.63 (s, 1H, 3-H), 3.52 (d, 1H, 7-H), 2.96 (s, 6H, -N(CH ₃) ₂)
40		5.81 (d, J=8.3Hz, 1H, 16-H), 4.62 (d, J=10.4Hz, 1H, 6-H), 3.69 (s, 1H, 3-H), 3.25-3.45 (m, 5H, 7-H, -OCH ₃), 1.92 (s, 3H, 34-CH ₃), 1.16 (s, 6H, 2 x CH ₃ (C-2'))
41		5.86 (d, 1H, 16-H), 4.74 (d, J=9.1Hz, 1H, 6-H), 3.32-3.79 (m, 4H, 3-H, 7-H, 2'-CH ₂)
42		5.82 (d, J=8.4Hz, 1H, 16-H), 4.58 (d, J=10.8Hz, 1H, 6-H), 4.50/4.26 (ddd, J=8.8Hz, H=13.2Hz, J=47.1Hz, 2H, -CH ₂ F), 3.70 (s, 1H, 3-H), 3.38 (s, 1H, 7-H), 1.93 (s, 3H, 34-CH ₃), 1.15-1.21 (m, cont. 6H, 2 x CH ₃ (C-2'))

The compounds of examples 2, 30, 31 and 34 in TABLE 1 are obtained analogously as described on Example 2, but using appropriate starting materials; all other compounds of TABLE 1 are obtained analogously as described in Example 1, but using appropriate starting materials.

Example 43

6-O-Methyl-24, 25-dihydro-Cephalosporin P1 (compound of formula I_P, wherein R is methyl)

A. 3-O-Benzoyloxymethyl-6-O-methyl-24, 25-dihydro-Cephalosporin P1 diphenylmethylester

0.67 ml of LiHMDS (1M in THF) are added to a solution of 500 mg of 3-O-Benzoyloxymethyl-6-deacetyl-Cephalosporin P1 diphenylmethylester in 5 ml of dry N,N-dimethylformamide at -10° and to the mixture obtained 0.06 ml of methyl iodide is added after 10 minutes. The mixture obtained is stirred at room temperature for 2 hours. The mixture obtained is poured onto ice and the mixture obtained is extracted three times with EtOAc. The organic layer obtained is dried, solvent is evaporated and the evaporation residue obtained is subjected to chromatography. 3-O-Benzoyloxymethyl-6-O-methyl-Cephalosporin P1 diphenylmethylester is obtained.





B. 6-O-Methyl-24, 25-dihydro-Cephalosporin P1

241 mg of 3-O-benzoyloxymethyl-6-O-methyl-Cephalosporin P1 diphenylmethylester are hydrogenated at 1 atm in the presence of Pd(OH)₂/C in 3ml of EtOAc overnight, the mixture obtained is filtered, solvent is evaporated and the evaporation residue is subjected to chromatography. 6-O-methyl-24, 25-dihydro-Cephalosporin P1 is obtained.


Analogously as described in Example 43, but using appropriate starting materials, compounds of formula I, wherein R is as defined in TABLE 2 below, are obtained.

¹H-NMR data (in DMSO, if not otherwise indicated) of the compounds are also set out in TABLE 2.

TABLE 2

EX	R	¹ H-NMR
43		5.65 (d, J=8.3Hz, 1H, 16-H), 3.34-3.53 (m, 2H, 3-H, 7-H), 3.19 (s, 3H, -OCH ₃), 2.80 (d, 1H, J=9.6Hz, 6-H)
44		5.66 (d, 1H, 16-H), 3.21-3.65 (m, 4H, -OCH ₂ , 3-H, 7-H), 2.91 (d, 1H, 6-H)
45		5.64 (d, J=8.3Hz, 1H, 16-H), 3.14-3.53 (m, 4H, -OCH ₂ , 3-H, 7-H), 2.88 (d, J=9.5Hz, 1H, 6-H)
46		5.54 (d, J=8.4Hz, 1H, 16-H), 3.08-3.40 (m, 4H, -OCH ₂ , 3-H, 7-H), 2.76 (d, J=9.2Hz, 1H, 6-H)

In TABLE 3 below there are listed mass spectroscopy data of intermediates of formula

VII_p

wherein R₁ is as defined in TABLE 3, useful in the production of a compound of formula I_p.

The numbers in column "EX", marked with an apostroph (e.g. 1'), are intermediates used in the production of a the corresponding compound of formula I_p in TABLE 1. E.g. the

- 5 intermediate "1'" in TABLE 3 is the intermediate used in the production of the compound of Example 1 in TABLE 1. Mass spectroscopy data (m/z (ESI)), also set out in TABLE 3, are determined by a Finnigan Navigator ThermoQuest LC/MS system.


TABLE 3

EX	Prot ₂	R ₁	Prot ₁	m/z (ESI)
1'	BOM	isopropyl	BOM	[M+Na] ⁺ = 865.5
2'	BOM	t.butyl	BOM	[M+Na] ⁺ = 879.5
3'	BOM	cyclopropyl	DPM	[M+Na] ⁺ = 909.4
4'	H	ethyl	DPM	[M+Na] ⁺ = 777.3
5'	H	n-propyl	DPM	[M+Cl] ⁻ = 803.4
6'	BOM	benzyloxymethyl	DPM	[M] ⁺ = 989.4
7'	BOM	n-hexyl	DPM	[M+Na] ⁺ = 953.5
8'	BOM	methoxymethyl	DPM	[M+Na] ⁺ = 914.1
9'	BOM	n-butyl	DPM	[M+Na] ⁺ = 925.0
10'	BOM	n-pentyl	DPM	[M+Na] ⁺ = 939.2
11'	BOM	methoxyethyl	DPM	[M+Na] ⁺ = 926.9
12'	BOM	hydrogen	DPM	[M+Na] ⁺ = 869.0
13'	BOM	methylcarbonylaminomethyl	DPM	[M+Cl] ⁻ = 951.9
14'	BOM	cyclopentyl	DPM	[M+Na] ⁺ = 937.0
15'	BOM	cyclobutyl	DPM	[M+Na] ⁺ = 923.0

EX	Prot ₂	R ₁	Prot ₁	m/z (ESI)
16'	BOM	isobutyl	DPM	[M+Na] ⁺ = 925.0
17'	BOM	N-benzoyloxycarbonyl-aminomethyl	DPM	[M+Na] ⁺ = 1031.8
18'	BOM	2-ethyl-propyl	DPM	[M+Na] ⁺ = 938.8
19'	BOM	t-butyl-methyl	DPM	[M+Na] ⁺ = 939.0
20'	BOM	cyclohexyl	DPM	[M+Na] ⁺ = 951.0
21'	BOM	ethoxymethyl	DPM	[M+Na] ⁺ = 927.1
22'	BOM	tetrahydrofuran-2-yl	DPM	[M+Na] ⁺ = 939.3
23'	BOM	tetrahydrofuran-3-yl	DPM	[M+Na] ⁺ = 939.3
24'	BOM	2-methyl-cyclopropyl	DPM	[M+Na] ⁺ = 923.2
25'	BOM	methoxy-ethoxy-methyl	BOM	[M+Na] ⁺ = 911.5
26'	BOM	di-trifluoromethyl-methyl	BOM	[M] ⁺ = 950.4
27'	BOM	methoxycarbonylethyl	BOM	[M+Na] ⁺ = 909.2
28'	BOM	4-methoxy-cyclohexyl	BOM	[M+Na] ⁺ = 935.5
29'	BOM	3-methoxy-cyclohexyl	BOM	[M+Na] ⁺ = 935.5
30'	BOM	adamantan-1-yl	BOM	[M+Na] ⁺ = 957.6
31'	BOM	1,1-dimethyl-propyl	BOM	[M+Na] ⁺ = 894.0
32'	BOM	2,2,3,3-tetramethyl-cyclopropyl	BOM	[M+Na] ⁺ = 919.0
33'	BOM	1-methyl-cyclopropyl	BOM	[M+Na] ⁺ = 877.4
34'	BOM	1,1-dimethyl-2-chloro-ethyl	BOM	[M+Na] ⁺ = 913.4
35'	BOM	(methoxy)(dimethyl)methyl	BOM	[M+Na] ⁺ = 895.4
36'	BOM	(n-propoxy)(dimethyl)methyl	BOM	[M+Na] ⁺ = 921.6
37'	BOM	3-dimethylamino-phenyl	BOM	[M+Na] ⁺ = 942.5
38'	BOM	(iso-propoxy)(dimethyl)methyl	BOM	[M+Na] ⁺ = 923.7
39'	BOM	4-dimethylamino-phenyl	BOM	[M+Na] ⁺ = 942.5
40'	BOM	1,1-dimethyl-2-methoxy-ethyl	BOM	[M+Na] ⁺ = 909.5
41'	BOM	benzyloxycarbonyl-methyl	BOM	[M+Na] ⁺ = 972.2
42'	BOM	1,1-dimethyl-2-fluoro-ethyl	BOM	[M+Na] ⁺ = 897.8

In TABLE 4 below there are listed mass spectroscopy data of intermediates of formula

- 29 -




wherein R'' is as defined in TABLE 4, useful in the production of a compound of formula I_P.
 The numbers in column "EX", marked with an apostroph (e.g. 43'), are intermediates used in
 the production of a the corresponding compound of formula I_P in TABLE 2. E.g. the
 5 intermediate "43'" in TABLE 4 is the intermediate used in the production of the compound of
 Example 43 in TABLE 2. Mass spectroscopy data (m/z (ESI)), also set out in TABLE 4, are
 determined by a Finnigan Navigator ThermoQuest LC/MS system.

TABLE 4

EX	Prot ₂	R''	Prot ₁	m/z (ESI)
43'	BOM	methyl	DPM	[M+Na] ⁺ = 855.1
44'	BOM	ethyl	DPM	[M+Na] ⁺ = 869.4
45'	BOM	n-propyl	DPM	[M+Na] ⁺ = 883.3
46'	BOM	n-hexyl	DPM	[M+Na] ⁺ = 925.5

Patent Claims

1. A compound of formula



5

wherein

R is hydrogen, CO-R₁ or (C₁₋₈)alkyl, such as methyl, ethyl, n-propyl or n-hexyl, and

R₁ is hydrogen, (C₁₋₈)alkyl, (C₃₋₈)cycloalkyl, (C₁₋₈)alkoxy-(C₁₋₆)alkyl,

(C₁₋₄)alkoxy-(C₁₋₄)alkoxy-(C₁₋₄)alkyl, amino(C₁₋₄)alkyl, halo(C₁₋₆)alkyl,

10

hydroxy(C₁₋₄)alkyl, carboxy(C₁₋₄)alkyl, (C₁₋₄)alkoxycarbonyl-(C₁₋₄)alkyl, (C₆₋₁₈)aryl,

heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from S, O or N, or bridged (C₇₋₁₂)cycloalkyl.

2. A compound of claim 1, wherein

15

R is hydrogen, (C₁₋₆)alkyl, or CO-R₁, and

R₁ is hydrogen, (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, e.g. unsubstituted (C₃₋₆)cycloalkyl or


(C₃₋₆)cycloalkyl substituted by one or more methyl or methoxy; (C₁₋₃)alkoxy-(C₁₋₃)alkyl,

methoxy-(C₁₋₂)alkoxy-(C₁₋₂)alkyl, aminomethyl, halo(C₁₋₄)alkyl, comprising one or two


20

halogen atoms; hydroxymethyl, carboxymethyl, methoxycarbonyl-(C₁₋₂)alkyl, phenyl,


3. A compound of any one of claims 1 or 2, wherein R is a group of formula



- 31 -




- 32 -



- 5 4. A compound of any one of claims 1 or 3 in the form of a salt.
5. A compound of any one of claims 1 to 4 for use as a pharmaceutical.
6. The use of a compound of any one of claims 1 to 4 for the manufacture of a medicament
10 for the treatment of microbial diseases.
7. A pharmaceutical composition comprising a compound of any one of claims 1 to 4 in association with at least one pharmaceutical excipient.
- 15 8. A pharmaceutical composition according to claim 7, further comprising another pharmaceutically active agent.
9. A method of treatment of microbial diseases, which treatment comprises administering to a subject in need of such treatment an effective amount of a compound of any one of
20 claims 1 to 4.
10. A compound of formula

- 33 -




wherein

Prot₁ is a protecting group, and

Prot₂ is either other than a protecting group, or is a protecting group, and


5 R'₁ has the meaning of R₁, as defined in any one of claims 1 to 4, and additionally includes residues as defined in R₁, wherein functional groups are protected.

11. A compound of formula




10 or of formula

- 34 -



12. A compound of formula




5 wherein Prot_1 and Prot_2 are as defined in claim 10, and R'' is (C_{1-8}) alkyl.

SC/3-Nov-03

Abstract

5

A compound of formula



wherein

10 R has various meanings and its use as a pharmaceutical.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.